TY  - JOUR
AU  - Milenković, Bojana
AU  - Šuljagić, Vesna
AU  - Perić, Aneta
AU  - Dragojević-Simić, Viktorija
AU  - Tarabar, Olivera
AU  - Milanović, Milomir
AU  - Putić, Vesna
AU  - Tomić, Diana
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4829
AB  - Background Clostridioides difficile infection (CDI) is one of the most common healthcare-associated (HA) infections. Cancer patients, particularly haemato-oncological patients, have an increased risk for CDI due to more risk factors compared with non-cancer patients. The aim of this study was to investigate differences in outcomes associated with HA CDI in patients with solid and haematological malignancies compared with patients with no underlying malignant disease in a tertiary healthcare centre in Serbia.

Methods A prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.

Results During a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).

Conclusions Patients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality.
PB  - British Medical Journal
T2  - European Journal of Hospital Pharmacy
T1  - Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study
VL  - 29
IS  - e1
SP  - e15
EP  - e22
DO  - 10.1136/ejhpharm-2020-002574
ER  - 

@article{
author = "Milenković, Bojana and Šuljagić, Vesna and Perić, Aneta and Dragojević-Simić, Viktorija and Tarabar, Olivera and Milanović, Milomir and Putić, Vesna and Tomić, Diana and Miljković, Branislava and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Background Clostridioides difficile infection (CDI) is one of the most common healthcare-associated (HA) infections. Cancer patients, particularly haemato-oncological patients, have an increased risk for CDI due to more risk factors compared with non-cancer patients. The aim of this study was to investigate differences in outcomes associated with HA CDI in patients with solid and haematological malignancies compared with patients with no underlying malignant disease in a tertiary healthcare centre in Serbia.

Methods A prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.

Results During a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).

Conclusions Patients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality.",
publisher = "British Medical Journal",
journal = "European Journal of Hospital Pharmacy",
title = "Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study",
volume = "29",
number = "e1",
pages = "e15-e22",
doi = "10.1136/ejhpharm-2020-002574"
}

Milenković, B., Šuljagić, V., Perić, A., Dragojević-Simić, V., Tarabar, O., Milanović, M., Putić, V., Tomić, D., Miljković, B.,& Vezmar-Kovačević, S.. (2022). Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. in European Journal of Hospital Pharmacy
British Medical Journal., 29(e1), e15-e22.
https://doi.org/10.1136/ejhpharm-2020-002574

Milenković B, Šuljagić V, Perić A, Dragojević-Simić V, Tarabar O, Milanović M, Putić V, Tomić D, Miljković B, Vezmar-Kovačević S. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. in European Journal of Hospital Pharmacy. 2022;29(e1):e15-e22.
doi:10.1136/ejhpharm-2020-002574 .

Milenković, Bojana, Šuljagić, Vesna, Perić, Aneta, Dragojević-Simić, Viktorija, Tarabar, Olivera, Milanović, Milomir, Putić, Vesna, Tomić, Diana, Miljković, Branislava, Vezmar-Kovačević, Sandra, "Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study" in European Journal of Hospital Pharmacy, 29, no. e1 (2022):e15-e22,
https://doi.org/10.1136/ejhpharm-2020-002574 . .

TY  - JOUR
AU  - Perić, Aneta
AU  - Udilović, Ana
AU  - Dobrić, Silva
AU  - Vezmar-Kovačević, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4017
AB  - Aims: The aim of this study was to analyse potential drug–drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices. Methods: This was a cross-sectional study including all outpatients with hypertension and two or more medications, treated in a university hospital in Serbia. Lexicomp Interact (Lexi-Comp, Inc., Hudson, OH) was used for identification of pDDIs and potential ADRs. Treatment choices were explored according to patient characteristics, treatment guidelines and the interacting potential of drugs. Data were analysed using descriptive analysis and multiple logistic regression. Results: A total of 350 patients were included in this study, with average age (77 [36–98] years and 6.1 [2.5]) medications. The majority of patients (86.0%) had at least one clinically significant pDDI, and the average was 3.78 (3.90) (range 1–25). Suggestions for treatment change aimed mainly at eliminating drug duplications, reducing the use of thiazide diuretics, sulfonylureas, alpha-lipoic acid and pentoxifylline and increasing the use of calcium-channel blockers, when appropriate. pDDIs would have decreased to 2.10 (2.52), P <.001, yet male gender, ≥6 medications, cardiovascular diseases, diabetes, benign prostatic hyperplasia, would be predictive of two or more pDDIs. The main potential adverse outcomes of pDDIs were hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis. Conclusion: Careful choice of drugs can reduce but not eliminate pDDIs and their potential ADRs in hypertensive patients. Close monitoring for hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis is necessary.
PB  - John Wiley and Sons Inc
T2  - British Journal of Clinical Pharmacology
T1  - The impact of treatment choices on potential drug–drug interactions in hypertensive patients
VL  - 88
IS  - 5
SP  - 2340
EP  - 2348
DO  - 10.1111/bcp.15168
ER  - 

@article{
author = "Perić, Aneta and Udilović, Ana and Dobrić, Silva and Vezmar-Kovačević, Sandra",
year = "2021",
abstract = "Aims: The aim of this study was to analyse potential drug–drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices. Methods: This was a cross-sectional study including all outpatients with hypertension and two or more medications, treated in a university hospital in Serbia. Lexicomp Interact (Lexi-Comp, Inc., Hudson, OH) was used for identification of pDDIs and potential ADRs. Treatment choices were explored according to patient characteristics, treatment guidelines and the interacting potential of drugs. Data were analysed using descriptive analysis and multiple logistic regression. Results: A total of 350 patients were included in this study, with average age (77 [36–98] years and 6.1 [2.5]) medications. The majority of patients (86.0%) had at least one clinically significant pDDI, and the average was 3.78 (3.90) (range 1–25). Suggestions for treatment change aimed mainly at eliminating drug duplications, reducing the use of thiazide diuretics, sulfonylureas, alpha-lipoic acid and pentoxifylline and increasing the use of calcium-channel blockers, when appropriate. pDDIs would have decreased to 2.10 (2.52), P <.001, yet male gender, ≥6 medications, cardiovascular diseases, diabetes, benign prostatic hyperplasia, would be predictive of two or more pDDIs. The main potential adverse outcomes of pDDIs were hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis. Conclusion: Careful choice of drugs can reduce but not eliminate pDDIs and their potential ADRs in hypertensive patients. Close monitoring for hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis is necessary.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Clinical Pharmacology",
title = "The impact of treatment choices on potential drug–drug interactions in hypertensive patients",
volume = "88",
number = "5",
pages = "2340-2348",
doi = "10.1111/bcp.15168"
}

Perić, A., Udilović, A., Dobrić, S.,& Vezmar-Kovačević, S.. (2021). The impact of treatment choices on potential drug–drug interactions in hypertensive patients. in British Journal of Clinical Pharmacology
John Wiley and Sons Inc., 88(5), 2340-2348.
https://doi.org/10.1111/bcp.15168

Perić A, Udilović A, Dobrić S, Vezmar-Kovačević S. The impact of treatment choices on potential drug–drug interactions in hypertensive patients. in British Journal of Clinical Pharmacology. 2021;88(5):2340-2348.
doi:10.1111/bcp.15168 .

Perić, Aneta, Udilović, Ana, Dobrić, Silva, Vezmar-Kovačević, Sandra, "The impact of treatment choices on potential drug–drug interactions in hypertensive patients" in British Journal of Clinical Pharmacology, 88, no. 5 (2021):2340-2348,
https://doi.org/10.1111/bcp.15168 . .

TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Barać, Aleksandra
AU  - Perić, Aneta
AU  - Vojvodić, Danilo
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3949
AB  - Background: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. Results: EPs 7630 increased concentrations of MCP-1 (P =.001) and IP-10 (P =.049) and decreased levels of MIP-1α (P <.001), ENA-78 (P <.001), and IL-8 (P <.001). Roxithromycin increased levels of IP-10 (P =.049) and decreased levels of MCP-1 (P <.001), MIP-1α (P <.016), ENA-78 (P <.001), and IL-8 (P <.001). Comparison of the non-treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P <.001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. Conclusion: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. Level of Evidence: 1b.
PB  - John Wiley and Sons Inc
T2  - Laryngoscope Investigative Otolaryngology
T1  - Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis
VL  - 6
IS  - 1
SP  - 25
EP  - 33
DO  - 10.1002/lio2.514
ER  - 

@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Barać, Aleksandra and Perić, Aneta and Vojvodić, Danilo",
year = "2021",
abstract = "Background: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. Results: EPs 7630 increased concentrations of MCP-1 (P =.001) and IP-10 (P =.049) and decreased levels of MIP-1α (P <.001), ENA-78 (P <.001), and IL-8 (P <.001). Roxithromycin increased levels of IP-10 (P =.049) and decreased levels of MCP-1 (P <.001), MIP-1α (P <.016), ENA-78 (P <.001), and IL-8 (P <.001). Comparison of the non-treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P <.001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. Conclusion: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. Level of Evidence: 1b.",
publisher = "John Wiley and Sons Inc",
journal = "Laryngoscope Investigative Otolaryngology",
title = "Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis",
volume = "6",
number = "1",
pages = "25-33",
doi = "10.1002/lio2.514"
}

Perić, A., Vezmar-Kovačević, S., Barać, A., Perić, A.,& Vojvodić, D.. (2021). Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. in Laryngoscope Investigative Otolaryngology
John Wiley and Sons Inc., 6(1), 25-33.
https://doi.org/10.1002/lio2.514

Perić A, Vezmar-Kovačević S, Barać A, Perić A, Vojvodić D. Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. in Laryngoscope Investigative Otolaryngology. 2021;6(1):25-33.
doi:10.1002/lio2.514 .

Perić, Aleksandar, Vezmar-Kovačević, Sandra, Barać, Aleksandra, Perić, Aneta, Vojvodić, Danilo, "Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis" in Laryngoscope Investigative Otolaryngology, 6, no. 1 (2021):25-33,
https://doi.org/10.1002/lio2.514 . .

TY  - JOUR
AU  - Šuljagić, Vesna
AU  - Milenković, Bojana
AU  - Perić, Aneta
AU  - Jovanović, Dragutin
AU  - Begović-Kuprešanin, Vesna
AU  - Starčević, Srđan
AU  - Tomić, Aleksanda
AU  - Vezmar-Kovačević, Sandra
AU  - Dragojević-Simić, Viktorija
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3549
AB  - Introduction: Clostridioides difficile (C. difficile) infection (CDI) is one of the most common healthcare-associated (HA) infections in contemporary medicine. The risk factors (RFs) for HA CDI in medical and surgical patients are poorly investigated in countries with a limited resource healthcare system. Therefore, the aim of the study was to investigate differences in patients’ characteristics, factors related to healthcare and outcomes associated with HA CDI in surgical and medical patients in tertiary healthcare centre in Serbia. Materials and Methods: A prospective cohort study was conducted including adult patients diagnosed with initial episode of HA CDI, first recurrence of disease, readmission to hospital, while deaths within 30 days of CDI diagnosis and in-hospital mortality were also recorded. Patients hospitalized for any non-surgical illness, who developed initial HA CDI were assigned to medical group, whereas those who developed initial HA CDI after surgical procedures were in surgical group. The data on patients’ characteristics and factors related to healthcare were collected, too. Results: During 7-year period, from 553 patients undergoing in-hospital treatment and diagnosed with CDI, 268 (48.5%) and 285 (51.5%) were surgical and medical patients, respectively. Age ≥ 65 years, use of proton pump inhibitors, chemotherapy and fluoroquinolones were positively associated with being in medical group, whereas admission to intensive care unit and use of second- and third-generation cephalosporins were positively associated with being in surgical group. Conclusions: Based on obtained results, including significant differences in 30-day mortality and in-hospital mortality, it can be concluded that medical patient were more endangered with HA CDI than surgical ones.
PB  - Taylor & Francis
T2  - Libyan Journal of Medicine
T1  - Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study
VL  - 15
IS  - 1
DO  - 10.1080/19932820.2019.1708639
ER  - 

@article{
author = "Šuljagić, Vesna and Milenković, Bojana and Perić, Aneta and Jovanović, Dragutin and Begović-Kuprešanin, Vesna and Starčević, Srđan and Tomić, Aleksanda and Vezmar-Kovačević, Sandra and Dragojević-Simić, Viktorija",
year = "2020",
abstract = "Introduction: Clostridioides difficile (C. difficile) infection (CDI) is one of the most common healthcare-associated (HA) infections in contemporary medicine. The risk factors (RFs) for HA CDI in medical and surgical patients are poorly investigated in countries with a limited resource healthcare system. Therefore, the aim of the study was to investigate differences in patients’ characteristics, factors related to healthcare and outcomes associated with HA CDI in surgical and medical patients in tertiary healthcare centre in Serbia. Materials and Methods: A prospective cohort study was conducted including adult patients diagnosed with initial episode of HA CDI, first recurrence of disease, readmission to hospital, while deaths within 30 days of CDI diagnosis and in-hospital mortality were also recorded. Patients hospitalized for any non-surgical illness, who developed initial HA CDI were assigned to medical group, whereas those who developed initial HA CDI after surgical procedures were in surgical group. The data on patients’ characteristics and factors related to healthcare were collected, too. Results: During 7-year period, from 553 patients undergoing in-hospital treatment and diagnosed with CDI, 268 (48.5%) and 285 (51.5%) were surgical and medical patients, respectively. Age ≥ 65 years, use of proton pump inhibitors, chemotherapy and fluoroquinolones were positively associated with being in medical group, whereas admission to intensive care unit and use of second- and third-generation cephalosporins were positively associated with being in surgical group. Conclusions: Based on obtained results, including significant differences in 30-day mortality and in-hospital mortality, it can be concluded that medical patient were more endangered with HA CDI than surgical ones.",
publisher = "Taylor & Francis",
journal = "Libyan Journal of Medicine",
title = "Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study",
volume = "15",
number = "1",
doi = "10.1080/19932820.2019.1708639"
}

Šuljagić, V., Milenković, B., Perić, A., Jovanović, D., Begović-Kuprešanin, V., Starčević, S., Tomić, A., Vezmar-Kovačević, S.,& Dragojević-Simić, V.. (2020). Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study. in Libyan Journal of Medicine
Taylor & Francis., 15(1).
https://doi.org/10.1080/19932820.2019.1708639

Šuljagić V, Milenković B, Perić A, Jovanović D, Begović-Kuprešanin V, Starčević S, Tomić A, Vezmar-Kovačević S, Dragojević-Simić V. Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study. in Libyan Journal of Medicine. 2020;15(1).
doi:10.1080/19932820.2019.1708639 .

Šuljagić, Vesna, Milenković, Bojana, Perić, Aneta, Jovanović, Dragutin, Begović-Kuprešanin, Vesna, Starčević, Srđan, Tomić, Aleksanda, Vezmar-Kovačević, Sandra, Dragojević-Simić, Viktorija, "Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study" in Libyan Journal of Medicine, 15, no. 1 (2020),
https://doi.org/10.1080/19932820.2019.1708639 . .

TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Barac, Aleksandra
AU  - Gacesa, Dejan
AU  - Perić, Aneta
AU  - Matković-Jozin, Svjetlana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3352
AB  - Background: Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs). Aim/objective: To compare effect of hypertonic (2.3% NaCl) sea water and isotonic 0.9% NaCl on symptoms and endoscopic findings in those patients in the period of 1 month after endoscopic sinus surgery (ESS). Material and methods: This prospective, randomized study included 30 patients with aspirin-induced CRS undergoing ESS. Patients were divided into two groups of 15 subjects and one of the two nasal irrigation solutions was administered in each group. Intensity of 5 symptoms (nasal obstruction, nasal discharge/postnasal drip, facial pain/pressure, headache and trouble sleeping) and endoscopic findings were assessed during the 1st, 7th, 14th, 21st and 28th days after the nasal packs removal. Results: We found significantly lower total symptom score (TSS) during the 7th (p= .009), 14th (p = .003), 21st (p  lt  .001) and the 28th day (p=.001), lower total endoscopic score (TES) on the 21st (p = .002) and 28th day (p = .001), lower nasal obstruction, facial pain/pressure, headache and trouble sleeping, and lower nasal mucosal edema, nasal secretion and nasal crusting in patients treated by hypertonic sea water. Conclusion and significance: Hypertonic sea water should be recommended douching solution in the early postoperative care of patients with aspirin-induced CRS.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Acta Oto-Laryngologica
T1  - Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery
VL  - 139
IS  - 6
SP  - 529
EP  - 535
DO  - 10.1080/00016489.2019.1605454
ER  - 

@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Barac, Aleksandra and Gacesa, Dejan and Perić, Aneta and Matković-Jozin, Svjetlana",
year = "2019",
abstract = "Background: Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs). Aim/objective: To compare effect of hypertonic (2.3% NaCl) sea water and isotonic 0.9% NaCl on symptoms and endoscopic findings in those patients in the period of 1 month after endoscopic sinus surgery (ESS). Material and methods: This prospective, randomized study included 30 patients with aspirin-induced CRS undergoing ESS. Patients were divided into two groups of 15 subjects and one of the two nasal irrigation solutions was administered in each group. Intensity of 5 symptoms (nasal obstruction, nasal discharge/postnasal drip, facial pain/pressure, headache and trouble sleeping) and endoscopic findings were assessed during the 1st, 7th, 14th, 21st and 28th days after the nasal packs removal. Results: We found significantly lower total symptom score (TSS) during the 7th (p= .009), 14th (p = .003), 21st (p  lt  .001) and the 28th day (p=.001), lower total endoscopic score (TES) on the 21st (p = .002) and 28th day (p = .001), lower nasal obstruction, facial pain/pressure, headache and trouble sleeping, and lower nasal mucosal edema, nasal secretion and nasal crusting in patients treated by hypertonic sea water. Conclusion and significance: Hypertonic sea water should be recommended douching solution in the early postoperative care of patients with aspirin-induced CRS.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Acta Oto-Laryngologica",
title = "Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery",
volume = "139",
number = "6",
pages = "529-535",
doi = "10.1080/00016489.2019.1605454"
}

Perić, A., Vezmar-Kovačević, S., Barac, A., Gacesa, D., Perić, A.,& Matković-Jozin, S.. (2019). Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. in Acta Oto-Laryngologica
Taylor & Francis Ltd, Abingdon., 139(6), 529-535.
https://doi.org/10.1080/00016489.2019.1605454

Perić A, Vezmar-Kovačević S, Barac A, Gacesa D, Perić A, Matković-Jozin S. Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. in Acta Oto-Laryngologica. 2019;139(6):529-535.
doi:10.1080/00016489.2019.1605454 .

Perić, Aleksandar, Vezmar-Kovačević, Sandra, Barac, Aleksandra, Gacesa, Dejan, Perić, Aneta, Matković-Jozin, Svjetlana, "Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery" in Acta Oto-Laryngologica, 139, no. 6 (2019):529-535,
https://doi.org/10.1080/00016489.2019.1605454 . .

TY  - JOUR
AU  - Perić, Aneta
AU  - Dragojević-Simić, Viktorija
AU  - Milenković, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Suljagić, Vesna
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3057
AB  - Introduction: Healthcare-associated infections (HAIs) and irrational use of antibiotics in healthcare settings are major global public health concerns. Surveillance of HAIs in intensive care units (ICU), surgical-site infections (SSIs), and Clostridium difficile infections (CDIs), together with implementation of antibiotic stewardship, are cornerstones of hospital infection prevention programs. The aim of this study was to evaluate antibiotic consumption, especially of broad spectrum antibiotics, in relation to HAI incidence density (ID). Methodology: The study was conducted from 2011 to 2016 in a tertiary hospital, the Military Medical Academy (MMA), in Belgrade, Serbia. Through regular hospital surveillance we identified all patients with a new HAI. Data on consumption of antibacterials for systemic use were expressed as defined daily dose per 100 bed days (DDD/100 BD). Results: The highest incidence density (ID) of HAI was observed among patients in surgical ICUs (47.2 per 1000 patient-days), while the highest incidence rate among SSI was 3.7%. Moreover, the highest ID of CDI in medical patients was 6.2 per 10,000 patient-days, while in surgical patients it was 4.3 per 10,000 patient-days. The most frequently used antibiotics were cephalosporins, aminoglycosides and carbapenems (16.0 +/- 2.3, 4.8 +/- 0.7, 4.3 f 0.7 DDD/100 BD, respectively). There was no significant correlation between consumption of any groups of antibiotics and ID of CDI in medical and surgical patients. Conclusion: The multidisciplinary healthcare team would have crucial importance in the implementation of the antibiotic stewardship program in order to decrease unnecessary exposures of patients treated in healthcare settings.
PB  - J Infection Developing Countries, Tramaniglio
T2  - Journal of Infection in Developing Countries
T1  - Antibiotic consumption and healthcare-associated infections in a tertiary hospital in Belgrade, Serbia from 2011 to 2016
VL  - 12
IS  - 10
SP  - 855
EP  - 863
DO  - 10.3855/jidc.10827
ER  - 

@article{
author = "Perić, Aneta and Dragojević-Simić, Viktorija and Milenković, Bojana and Vezmar-Kovačević, Sandra and Suljagić, Vesna",
year = "2018",
abstract = "Introduction: Healthcare-associated infections (HAIs) and irrational use of antibiotics in healthcare settings are major global public health concerns. Surveillance of HAIs in intensive care units (ICU), surgical-site infections (SSIs), and Clostridium difficile infections (CDIs), together with implementation of antibiotic stewardship, are cornerstones of hospital infection prevention programs. The aim of this study was to evaluate antibiotic consumption, especially of broad spectrum antibiotics, in relation to HAI incidence density (ID). Methodology: The study was conducted from 2011 to 2016 in a tertiary hospital, the Military Medical Academy (MMA), in Belgrade, Serbia. Through regular hospital surveillance we identified all patients with a new HAI. Data on consumption of antibacterials for systemic use were expressed as defined daily dose per 100 bed days (DDD/100 BD). Results: The highest incidence density (ID) of HAI was observed among patients in surgical ICUs (47.2 per 1000 patient-days), while the highest incidence rate among SSI was 3.7%. Moreover, the highest ID of CDI in medical patients was 6.2 per 10,000 patient-days, while in surgical patients it was 4.3 per 10,000 patient-days. The most frequently used antibiotics were cephalosporins, aminoglycosides and carbapenems (16.0 +/- 2.3, 4.8 +/- 0.7, 4.3 f 0.7 DDD/100 BD, respectively). There was no significant correlation between consumption of any groups of antibiotics and ID of CDI in medical and surgical patients. Conclusion: The multidisciplinary healthcare team would have crucial importance in the implementation of the antibiotic stewardship program in order to decrease unnecessary exposures of patients treated in healthcare settings.",
publisher = "J Infection Developing Countries, Tramaniglio",
journal = "Journal of Infection in Developing Countries",
title = "Antibiotic consumption and healthcare-associated infections in a tertiary hospital in Belgrade, Serbia from 2011 to 2016",
volume = "12",
number = "10",
pages = "855-863",
doi = "10.3855/jidc.10827"
}

Perić, A., Dragojević-Simić, V., Milenković, B., Vezmar-Kovačević, S.,& Suljagić, V.. (2018). Antibiotic consumption and healthcare-associated infections in a tertiary hospital in Belgrade, Serbia from 2011 to 2016. in Journal of Infection in Developing Countries
J Infection Developing Countries, Tramaniglio., 12(10), 855-863.
https://doi.org/10.3855/jidc.10827

Perić A, Dragojević-Simić V, Milenković B, Vezmar-Kovačević S, Suljagić V. Antibiotic consumption and healthcare-associated infections in a tertiary hospital in Belgrade, Serbia from 2011 to 2016. in Journal of Infection in Developing Countries. 2018;12(10):855-863.
doi:10.3855/jidc.10827 .

Perić, Aneta, Dragojević-Simić, Viktorija, Milenković, Bojana, Vezmar-Kovačević, Sandra, Suljagić, Vesna, "Antibiotic consumption and healthcare-associated infections in a tertiary hospital in Belgrade, Serbia from 2011 to 2016" in Journal of Infection in Developing Countries, 12, no. 10 (2018):855-863,
https://doi.org/10.3855/jidc.10827 . .

TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Gacesa, Dejan
AU  - Perić, Aneta
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2868
AB  - Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.
PB  - Deomed Publ, Istanbul, Istanbul
T2  - ENT Updates
T1  - Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray
VL  - 7
IS  - 2
SP  - 68
EP  - 74
DO  - 10.2399/jmu.2017002003
ER  - 

@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Gacesa, Dejan and Perić, Aneta",
year = "2017",
abstract = "Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.",
publisher = "Deomed Publ, Istanbul, Istanbul",
journal = "ENT Updates",
title = "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray",
volume = "7",
number = "2",
pages = "68-74",
doi = "10.2399/jmu.2017002003"
}

Perić, A., Vezmar-Kovačević, S., Gacesa, D.,& Perić, A.. (2017). Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray. in ENT Updates
Deomed Publ, Istanbul, Istanbul., 7(2), 68-74.
https://doi.org/10.2399/jmu.2017002003

Perić A, Vezmar-Kovačević S, Gacesa D, Perić A. Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray. in ENT Updates. 2017;7(2):68-74.
doi:10.2399/jmu.2017002003 .

Perić, Aleksandar, Vezmar-Kovačević, Sandra, Gacesa, Dejan, Perić, Aneta, "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray" in ENT Updates, 7, no. 2 (2017):68-74,
https://doi.org/10.2399/jmu.2017002003 . .

TY  - JOUR
AU  - Perić, Aneta
AU  - Šurbatović, Maja
AU  - Vezmar-Kovačević, Sandra
AU  - Antunović, Mirjana
AU  - Veljović, Milić
AU  - Krstić-Lečić, Ivana
AU  - Đorđević, Dragan
AU  - Kilibarda, Vesna
AU  - Zeba, Snježana
AU  - Dobrić, Silva
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2473
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Beta-lactam antibiotics use in intensive care units: The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach
T1  - Upotreba beta-laktamskih antibiotika u jedinicama intenzivne terapije - patofiziološki, farmakokinetički, farmakodinamički i farmakoekonomski pristup
VL  - 72
IS  - 2
SP  - 175
EP  - 180
DO  - 10.2298/VSP1502175P
ER  - 

@article{
author = "Perić, Aneta and Šurbatović, Maja and Vezmar-Kovačević, Sandra and Antunović, Mirjana and Veljović, Milić and Krstić-Lečić, Ivana and Đorđević, Dragan and Kilibarda, Vesna and Zeba, Snježana and Dobrić, Silva",
year = "2015",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Beta-lactam antibiotics use in intensive care units: The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach, Upotreba beta-laktamskih antibiotika u jedinicama intenzivne terapije - patofiziološki, farmakokinetički, farmakodinamički i farmakoekonomski pristup",
volume = "72",
number = "2",
pages = "175-180",
doi = "10.2298/VSP1502175P"
}

Perić, A., Šurbatović, M., Vezmar-Kovačević, S., Antunović, M., Veljović, M., Krstić-Lečić, I., Đorđević, D., Kilibarda, V., Zeba, S.,& Dobrić, S.. (2015). Beta-lactam antibiotics use in intensive care units: The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 72(2), 175-180.
https://doi.org/10.2298/VSP1502175P

Perić A, Šurbatović M, Vezmar-Kovačević S, Antunović M, Veljović M, Krstić-Lečić I, Đorđević D, Kilibarda V, Zeba S, Dobrić S. Beta-lactam antibiotics use in intensive care units: The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach. in Vojnosanitetski pregled. 2015;72(2):175-180.
doi:10.2298/VSP1502175P .

Perić, Aneta, Šurbatović, Maja, Vezmar-Kovačević, Sandra, Antunović, Mirjana, Veljović, Milić, Krstić-Lečić, Ivana, Đorđević, Dragan, Kilibarda, Vesna, Zeba, Snježana, Dobrić, Silva, "Beta-lactam antibiotics use in intensive care units: The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach" in Vojnosanitetski pregled, 72, no. 2 (2015):175-180,
https://doi.org/10.2298/VSP1502175P . .

TY  - JOUR
AU  - Perić, Aneta
AU  - Šurbatović, Maja
AU  - Vezmar-Kovačević, Sandra
AU  - Antunović, Mirjana
AU  - Veljović, Milić
AU  - Đorđević, Dragan
AU  - Anđelić, Tamara
AU  - Zeba, Snježana
AU  - Dobrić, Silva
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2262
AB  - Background/Aim. Critically ill patients are at very high risk of developing severe infections in intensive care units (ICUs). Procalcitonin (PCT) levels are eleveted in the circulation in patients with bacterial sepsis and PCT might be useful in guiding antibiotic treatment. The aim of this study was to estimate factors influencing patients survival and treatment cost in ICU with special emphasis on the impact of PCT serum levels use in guiding antimicrobial therapy. Methods. The study was conducted from August 2010 to May 2012 in the Intensive Therapy Unit, Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy (MMA), Belgrade, Serbia. All adult critically ill patients with sepsis and/or trauma admitted in the ICU were included in the study. This study included only the cost of antimicrobial therapy in the ICU and the cost for PCT analysis. We used prices valid in the MMA for the year 2012. PCT in serum was measured by homogeneous immunoassay on a Brahms Kryptor analyzer. Results. A total of 102 patients were enrolled. The mean patients age was 55 ± 19 years and 61.8% of patients were male. The mean length of stay (LOS) in the ICU was 12 ± 21 days. There was a statistically significant difference (p  lt  0.001) between the sepsis and trauma group regarding outcome (higher mortality rate was in the sepsis group, particularly in the patients with peritonitis who were mostly women). The patients younger than 70 years had better chance of survival. LOS, the use of carbapenems and PCT-measurement influenced the cost of therapy in the ICU. Conclusions. The obtained results show that age, the diagnosis and gender were the main predictors of survival of critically ill patients in the ICU. The cost of ICU stay was dependent on LOS, use of carbapenems and PCT measurement although the influence of these three factors on the outcome in the patients did not reach a statistical significance.
AB  - Uvod/Cilj. Kritično oboleli pacijenti imaju veliki rizik od razvoja teških infekcija u jedinicama intenzivne terapije (JIT). Nivo prokalcitonina (PCT) u cirkulaciji je povišen kod bolesnika sa bakterijskom sepsom, tako da PCT može biti koristan u praćenju antibiotske terapije. Cilj ove studije bio je da se ustanove faktori koji utiču na ishod i troškove lečenja u JIT u našoj ustanovi sa posebnim naglaskom na uticaj korišćenja serumskog nivoa PCT u vođenju antimikrobne terapije. Metode. Studija je sprovedena od avgusta 2010. godine do maja 2012. godine u Jedinici intenzivne terapije Klinike za anesteziologiju i intenzivnu terapiju Vojnomedicinske akademije (VMA) u Beogradu, Srbija. Svi kritično oboleli sa sepsom i/ili traumom koji su primljeni u JIT bili su uključeni u studiju. Studijom su obuhvaćeni samo troškovi antimikrobne terapije u JIT i troškovi PCT analize. Koristili smo cenovnik VMA za 2012. godinu. PCT u serumu je meren tehnikom homogenog imunoeseja na Brams Kriptor analizatoru. Rezultati. Studijom su bila obuhvaćena 102 bolesnika. Prosečna starost bolesnika iznosila je 55 ± 19 godina, a 61,8% bolesnika bili su muškarci. Prosečna dužina boravka u JIT (lenght of stay LOS) iznosila je 12 ± 21 dana. Postojala je statistički značajna razlika (p  lt  0.001) između ishoda lečenja u grupi sa sepsom u odnosu na grupu sa traumom. Bolesnici mlađi od 70 godina imali su bolju šansu da prežive. Dužina boravka, upotreba karbapenema i merenje PCT uticali su na cenu terapije u JIT. Zaključak. Dobijeni rezultati pokazuju da su godine života, dijagnoza i pol bili glavni prediktori preživljavanja kritično obolelih u JIT. Cena terapije zavisila je od dužine boravka u JIT, upotrebe karbapenema i merenja PCT, ali uticaj ovih faktora na ishod lečenja nije dostigao statističku značajnost.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study
T1  - Faktori koji utiču na cenu antibiotske terapije i ishod kod kritično obolelih pacijenata - 'real-life' studija
VL  - 71
IS  - 12
SP  - 1102
EP  - 1108
DO  - 10.2298/VSP1412102P
ER  - 

@article{
author = "Perić, Aneta and Šurbatović, Maja and Vezmar-Kovačević, Sandra and Antunović, Mirjana and Veljović, Milić and Đorđević, Dragan and Anđelić, Tamara and Zeba, Snježana and Dobrić, Silva",
year = "2014",
abstract = "Background/Aim. Critically ill patients are at very high risk of developing severe infections in intensive care units (ICUs). Procalcitonin (PCT) levels are eleveted in the circulation in patients with bacterial sepsis and PCT might be useful in guiding antibiotic treatment. The aim of this study was to estimate factors influencing patients survival and treatment cost in ICU with special emphasis on the impact of PCT serum levels use in guiding antimicrobial therapy. Methods. The study was conducted from August 2010 to May 2012 in the Intensive Therapy Unit, Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy (MMA), Belgrade, Serbia. All adult critically ill patients with sepsis and/or trauma admitted in the ICU were included in the study. This study included only the cost of antimicrobial therapy in the ICU and the cost for PCT analysis. We used prices valid in the MMA for the year 2012. PCT in serum was measured by homogeneous immunoassay on a Brahms Kryptor analyzer. Results. A total of 102 patients were enrolled. The mean patients age was 55 ± 19 years and 61.8% of patients were male. The mean length of stay (LOS) in the ICU was 12 ± 21 days. There was a statistically significant difference (p  lt  0.001) between the sepsis and trauma group regarding outcome (higher mortality rate was in the sepsis group, particularly in the patients with peritonitis who were mostly women). The patients younger than 70 years had better chance of survival. LOS, the use of carbapenems and PCT-measurement influenced the cost of therapy in the ICU. Conclusions. The obtained results show that age, the diagnosis and gender were the main predictors of survival of critically ill patients in the ICU. The cost of ICU stay was dependent on LOS, use of carbapenems and PCT measurement although the influence of these three factors on the outcome in the patients did not reach a statistical significance., Uvod/Cilj. Kritično oboleli pacijenti imaju veliki rizik od razvoja teških infekcija u jedinicama intenzivne terapije (JIT). Nivo prokalcitonina (PCT) u cirkulaciji je povišen kod bolesnika sa bakterijskom sepsom, tako da PCT može biti koristan u praćenju antibiotske terapije. Cilj ove studije bio je da se ustanove faktori koji utiču na ishod i troškove lečenja u JIT u našoj ustanovi sa posebnim naglaskom na uticaj korišćenja serumskog nivoa PCT u vođenju antimikrobne terapije. Metode. Studija je sprovedena od avgusta 2010. godine do maja 2012. godine u Jedinici intenzivne terapije Klinike za anesteziologiju i intenzivnu terapiju Vojnomedicinske akademije (VMA) u Beogradu, Srbija. Svi kritično oboleli sa sepsom i/ili traumom koji su primljeni u JIT bili su uključeni u studiju. Studijom su obuhvaćeni samo troškovi antimikrobne terapije u JIT i troškovi PCT analize. Koristili smo cenovnik VMA za 2012. godinu. PCT u serumu je meren tehnikom homogenog imunoeseja na Brams Kriptor analizatoru. Rezultati. Studijom su bila obuhvaćena 102 bolesnika. Prosečna starost bolesnika iznosila je 55 ± 19 godina, a 61,8% bolesnika bili su muškarci. Prosečna dužina boravka u JIT (lenght of stay LOS) iznosila je 12 ± 21 dana. Postojala je statistički značajna razlika (p  lt  0.001) između ishoda lečenja u grupi sa sepsom u odnosu na grupu sa traumom. Bolesnici mlađi od 70 godina imali su bolju šansu da prežive. Dužina boravka, upotreba karbapenema i merenje PCT uticali su na cenu terapije u JIT. Zaključak. Dobijeni rezultati pokazuju da su godine života, dijagnoza i pol bili glavni prediktori preživljavanja kritično obolelih u JIT. Cena terapije zavisila je od dužine boravka u JIT, upotrebe karbapenema i merenja PCT, ali uticaj ovih faktora na ishod lečenja nije dostigao statističku značajnost.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study, Faktori koji utiču na cenu antibiotske terapije i ishod kod kritično obolelih pacijenata - 'real-life' studija",
volume = "71",
number = "12",
pages = "1102-1108",
doi = "10.2298/VSP1412102P"
}

Perić, A., Šurbatović, M., Vezmar-Kovačević, S., Antunović, M., Veljović, M., Đorđević, D., Anđelić, T., Zeba, S.,& Dobrić, S.. (2014). Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 71(12), 1102-1108.
https://doi.org/10.2298/VSP1412102P

Perić A, Šurbatović M, Vezmar-Kovačević S, Antunović M, Veljović M, Đorđević D, Anđelić T, Zeba S, Dobrić S. Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study. in Vojnosanitetski pregled. 2014;71(12):1102-1108.
doi:10.2298/VSP1412102P .

Perić, Aneta, Šurbatović, Maja, Vezmar-Kovačević, Sandra, Antunović, Mirjana, Veljović, Milić, Đorđević, Dragan, Anđelić, Tamara, Zeba, Snježana, Dobrić, Silva, "Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study" in Vojnosanitetski pregled, 71, no. 12 (2014):1102-1108,
https://doi.org/10.2298/VSP1412102P . .

TY  - JOUR
AU  - Perić, Aneta
AU  - Toskić-Radojičić, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Antunović, Mirjana
AU  - Bojić, Vedrana
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2049
AB  - Introduction and objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with anti-inflammatory, analgetic and antipyretic properties and are used in the treatment of acute mild to moderate pain, chronic pain and inflammatory conditions and fever. The aim of the study was to analyze the consumption of NSAIDs, purpose of use, length of therapy, adverse effects and patient's perception about efficacy and safety of the drugs. All patients, who had a NSAID prescribed, were included in the study. Method: The research was done in the Military Medical Academy, Belgrade, Serbia from June to December 2008. A questionnaire filled with the assistance of a pharmacist, contained questions about co morbidities, use and adverse effects of NSAIDs. All patients with at least one NSAID prespription (diclofenac, ibuprofen, flurbiprofen, naproxen, piroxicam, tenoxicam, meloxicam) were included in the study. The responses were statistically processed using the /-test. Results: 160 patients were included in the study. The majority of the patients (59.4%) used one NSAID in tablet form (48.8%). The most frequent used were diclofenac and ibuprofen. 51.9% suffered from rheumatic diseases for more than 5 years. Every other patient used both NSAIDs and gastroprotective drugs, most often ranitidine (58.1%). Conclusion: The results show that rheumatic diseases are often present in older patients and that treatment with NSAIDs lasts longer than five years. Mild gastric problems have been recorded as adverse effects of NSAIDs, most often nausea and pain in the stomach. This is probably due to the frequent use of diclofenac and ibuprofen, drugs with low or moderate risk for gastric toxicity as well as the concomitant use of H2-antagonists and proton pump inhibitors.
AB  - Uvod i cilj rada: Nesteroidni antiinflamatorni lekovi (NSAIL) ispoljavaju antiinflamatorno, analgetičko i antipiretičko dejstvo i primenjuju se kod akutnih bolova blagog do umerenog intenziteta, hroničnih bolnih i zapaljenskih stanja, te povišene telesne temperature. Cilj ove studije bio je da se analizira vanbolnička potrošnja NSAIL, način primene, dužina terapije i neželjene reakcije, kao i iskustva pacijenata u vezi sa efikasnošću i bezbednošću lekova. U studiju su uključeni svi pacijenti kojima je propisan NSAIL. Metode: Istraživanje je sprovedeno u Vojnomedicinskoj akademiji u Beogradu, u periodu od juna do decembra 2008. godine. Pacijenti su, uz pomoć farmaceuta, popunjavali upitnik koji se sastojao od pitanja vezanih za pridružena oboljenja, upotrebu i neželjene efekte NSAIL. U studiju su uključeni svi pacijenti kojima je na recept bio propisan neki od NSAIL (diklofenak, ibuprofen, flurbiprofen, naproksen, piroksikam, tenoksikam, meloksikam). Odgovori su statistički obrađeni primenom x2-testa. Rezultati: U studiji je učestvovalo 160 pacijenata. Većina pacijenata (59,4%) je koristila jedan NSAIL, 48,8% ispitanika je primenjivalo lek u obliku tablete. Diklofenak i ibuprofen su najčešće korišćeni lekovi. U ispitivanoj grupi pacijenata, 51,9% pacijenata je bolovalo od reumatične bolesti duže od 5 godina. Svaki drugi pacijent je istovremeno primenjivao NSAIL i gastroprotektivni lek, najčešće ranitidin (58,1%). Zaključak: Rezultati pokazuju da se NSAIL često primenjuju duže od pet godina, u lečenju reumatičnih bolesti koje su zastupljene kod starijih pacijenata. Najčešći neželjeni efekti NSAIL su blagi gastrointestinalni problemi, nauzeja i bol u stomaku. Ovo se objašnjava time što se najviše koriste diklofenak i ibuprofen, lekovi koji imaju slab ili umeren rizik za ispoljavanje gastričnih neželjenih efekata, ali i zbog istovremene primene NSAIL i H2-blokatora/inhibitora protonske pumpe.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study
T1  - Vanbolnička primena nesteroidnih anti-inflamatornih lekova u Srbiji - opservaciona studija
VL  - 63
IS  - 5
SP  - 431
EP  - 442
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2049
ER  - 

@article{
author = "Perić, Aneta and Toskić-Radojičić, Marija and Vezmar-Kovačević, Sandra and Miljković, Branislava and Antunović, Mirjana and Bojić, Vedrana",
year = "2013",
abstract = "Introduction and objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with anti-inflammatory, analgetic and antipyretic properties and are used in the treatment of acute mild to moderate pain, chronic pain and inflammatory conditions and fever. The aim of the study was to analyze the consumption of NSAIDs, purpose of use, length of therapy, adverse effects and patient's perception about efficacy and safety of the drugs. All patients, who had a NSAID prescribed, were included in the study. Method: The research was done in the Military Medical Academy, Belgrade, Serbia from June to December 2008. A questionnaire filled with the assistance of a pharmacist, contained questions about co morbidities, use and adverse effects of NSAIDs. All patients with at least one NSAID prespription (diclofenac, ibuprofen, flurbiprofen, naproxen, piroxicam, tenoxicam, meloxicam) were included in the study. The responses were statistically processed using the /-test. Results: 160 patients were included in the study. The majority of the patients (59.4%) used one NSAID in tablet form (48.8%). The most frequent used were diclofenac and ibuprofen. 51.9% suffered from rheumatic diseases for more than 5 years. Every other patient used both NSAIDs and gastroprotective drugs, most often ranitidine (58.1%). Conclusion: The results show that rheumatic diseases are often present in older patients and that treatment with NSAIDs lasts longer than five years. Mild gastric problems have been recorded as adverse effects of NSAIDs, most often nausea and pain in the stomach. This is probably due to the frequent use of diclofenac and ibuprofen, drugs with low or moderate risk for gastric toxicity as well as the concomitant use of H2-antagonists and proton pump inhibitors., Uvod i cilj rada: Nesteroidni antiinflamatorni lekovi (NSAIL) ispoljavaju antiinflamatorno, analgetičko i antipiretičko dejstvo i primenjuju se kod akutnih bolova blagog do umerenog intenziteta, hroničnih bolnih i zapaljenskih stanja, te povišene telesne temperature. Cilj ove studije bio je da se analizira vanbolnička potrošnja NSAIL, način primene, dužina terapije i neželjene reakcije, kao i iskustva pacijenata u vezi sa efikasnošću i bezbednošću lekova. U studiju su uključeni svi pacijenti kojima je propisan NSAIL. Metode: Istraživanje je sprovedeno u Vojnomedicinskoj akademiji u Beogradu, u periodu od juna do decembra 2008. godine. Pacijenti su, uz pomoć farmaceuta, popunjavali upitnik koji se sastojao od pitanja vezanih za pridružena oboljenja, upotrebu i neželjene efekte NSAIL. U studiju su uključeni svi pacijenti kojima je na recept bio propisan neki od NSAIL (diklofenak, ibuprofen, flurbiprofen, naproksen, piroksikam, tenoksikam, meloksikam). Odgovori su statistički obrađeni primenom x2-testa. Rezultati: U studiji je učestvovalo 160 pacijenata. Većina pacijenata (59,4%) je koristila jedan NSAIL, 48,8% ispitanika je primenjivalo lek u obliku tablete. Diklofenak i ibuprofen su najčešće korišćeni lekovi. U ispitivanoj grupi pacijenata, 51,9% pacijenata je bolovalo od reumatične bolesti duže od 5 godina. Svaki drugi pacijent je istovremeno primenjivao NSAIL i gastroprotektivni lek, najčešće ranitidin (58,1%). Zaključak: Rezultati pokazuju da se NSAIL često primenjuju duže od pet godina, u lečenju reumatičnih bolesti koje su zastupljene kod starijih pacijenata. Najčešći neželjeni efekti NSAIL su blagi gastrointestinalni problemi, nauzeja i bol u stomaku. Ovo se objašnjava time što se najviše koriste diklofenak i ibuprofen, lekovi koji imaju slab ili umeren rizik za ispoljavanje gastričnih neželjenih efekata, ali i zbog istovremene primene NSAIL i H2-blokatora/inhibitora protonske pumpe.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study, Vanbolnička primena nesteroidnih anti-inflamatornih lekova u Srbiji - opservaciona studija",
volume = "63",
number = "5",
pages = "431-442",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2049"
}

Perić, A., Toskić-Radojičić, M., Vezmar-Kovačević, S., Miljković, B., Antunović, M.,& Bojić, V.. (2013). Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 63(5), 431-442.
https://hdl.handle.net/21.15107/rcub_farfar_2049

Perić A, Toskić-Radojičić M, Vezmar-Kovačević S, Miljković B, Antunović M, Bojić V. Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study. in Arhiv za farmaciju. 2013;63(5):431-442.
https://hdl.handle.net/21.15107/rcub_farfar_2049 .

Perić, Aneta, Toskić-Radojičić, Marija, Vezmar-Kovačević, Sandra, Miljković, Branislava, Antunović, Mirjana, Bojić, Vedrana, "Use of non-steroidal anti-inflammatory drugs in outpatients in Serbia: Observational study" in Arhiv za farmaciju, 63, no. 5 (2013):431-442,
https://hdl.handle.net/21.15107/rcub_farfar_2049 .

TY  - JOUR
AU  - Perić, Aneta
AU  - Toskić-Radojičić, Marija
AU  - Dobrić, Silva
AU  - Damjanov, Nemanja
AU  - Miljković, Branislava
AU  - Antunović, Mirjana
AU  - Vezmar, Sandra
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1366
AB  - Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.
PB  - Wiley-Blackwell, Malden
T2  - Journal of Evaluation in Clinical Practice
T1  - Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?
VL  - 16
IS  - 6
SP  - 1090
EP  - 1095
DO  - 10.1111/j.1365-2753.2009.01258.x
ER  - 

@article{
author = "Perić, Aneta and Toskić-Radojičić, Marija and Dobrić, Silva and Damjanov, Nemanja and Miljković, Branislava and Antunović, Mirjana and Vezmar, Sandra",
year = "2010",
abstract = "Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.",
publisher = "Wiley-Blackwell, Malden",
journal = "Journal of Evaluation in Clinical Practice",
title = "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?",
volume = "16",
number = "6",
pages = "1090-1095",
doi = "10.1111/j.1365-2753.2009.01258.x"
}

Perić, A., Toskić-Radojičić, M., Dobrić, S., Damjanov, N., Miljković, B., Antunović, M.,& Vezmar, S.. (2010). Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice
Wiley-Blackwell, Malden., 16(6), 1090-1095.
https://doi.org/10.1111/j.1365-2753.2009.01258.x

Perić A, Toskić-Radojičić M, Dobrić S, Damjanov N, Miljković B, Antunović M, Vezmar S. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice. 2010;16(6):1090-1095.
doi:10.1111/j.1365-2753.2009.01258.x .

Perić, Aneta, Toskić-Radojičić, Marija, Dobrić, Silva, Damjanov, Nemanja, Miljković, Branislava, Antunović, Mirjana, Vezmar, Sandra, "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?" in Journal of Evaluation in Clinical Practice, 16, no. 6 (2010):1090-1095,
https://doi.org/10.1111/j.1365-2753.2009.01258.x . .